318 related articles for article (PubMed ID: 12609799)
1. [Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].
Ségal-Bendirdjian E; Hillion J; Belmokhtar CA
Bull Cancer; 2003 Jan; 90(1):9-17. PubMed ID: 12609799
[TBL] [Abstract][Full Text] [Related]
2. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge].
Belka C; Betsch A; Marini P; Jendrossek V; Bamberg M; Budach W
Strahlenther Onkol; 2003 Mar; 179(3):141-51. PubMed ID: 12627256
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
4. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells.
Lacour S; Micheau O; Hammann A; Drouineaud V; Tschopp J; Solary E; Dimanche-Boitrel MT
Oncogene; 2003 Mar; 22(12):1807-16. PubMed ID: 12660816
[TBL] [Abstract][Full Text] [Related]
6. [Cell death signalling: recent advances and therapeutic application].
Ségal-Bendirdjian E; Dudognon C; Mathieu J; Hillion J; Besançon F
Bull Cancer; 2005 Jan; 92(1):23-35. PubMed ID: 15689323
[TBL] [Abstract][Full Text] [Related]
7. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
8. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and cancer: when BAX is TRAILing away.
Roth W; Reed JC
Nat Med; 2002 Mar; 8(3):216-8. PubMed ID: 11875486
[No Abstract] [Full Text] [Related]
11. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
12. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis.
He Q; Montalbano J; Corcoran C; Jin W; Huang Y; Sheikh MS
Oncogene; 2003 May; 22(17):2674-9. PubMed ID: 12730681
[TBL] [Abstract][Full Text] [Related]
13. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
[TBL] [Abstract][Full Text] [Related]
14. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
Izeradjene K; Douglas L; Delaney AB; Houghton JA
Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
[TBL] [Abstract][Full Text] [Related]
15. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
Nyormoi O; Mills L; Bar-Eli M
Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-based therapies and drug targets.
Fischer U; Schulze-Osthoff K
Cell Death Differ; 2005 Aug; 12 Suppl 1():942-61. PubMed ID: 15665817
[TBL] [Abstract][Full Text] [Related]
17. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
18. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Odoux C; Albers A
Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
20. Apo2L/TRAIL and its death and decoy receptors.
LeBlanc HN; Ashkenazi A
Cell Death Differ; 2003 Jan; 10(1):66-75. PubMed ID: 12655296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
